These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32683996)

  • 61. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
    Baghel S; Cathcart H; O'Reilly NJ
    J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pairwise polymer blends for oral drug delivery.
    Marks JA; Wegiel LA; Taylor LS; Edgar KJ
    J Pharm Sci; 2014 Sep; 103(9):2871-2883. PubMed ID: 24823790
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Oral formulation strategies to improve solubility of poorly water-soluble drugs.
    Singh A; Worku ZA; Van den Mooter G
    Expert Opin Drug Deliv; 2011 Oct; 8(10):1361-78. PubMed ID: 21810062
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nano-sized Solid Dispersions for Improving the Bioavailability of Poorly Water-soluble Drugs.
    Tran PHL; Tran TTD
    Curr Pharm Des; 2020; 26(38):4917-4924. PubMed ID: 32611298
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exploring oral nanoemulsions for bioavailability enhancement of poorly water-soluble drugs.
    Kotta S; Khan AW; Pramod K; Ansari SH; Sharma RK; Ali J
    Expert Opin Drug Deliv; 2012 May; 9(5):585-98. PubMed ID: 22512597
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of Poorly Soluble Drugs' Dissolution Rate by Laser Scattering in Different Water Isotopologues.
    Uspenskaya EV; Pleteneva TV; Kazimova IV; Syroeshkin AV
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33498881
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Amorphous solid dispersions: a robust platform to address bioavailability challenges.
    Newman A; Nagapudi K; Wenslow R
    Ther Deliv; 2015 Feb; 6(2):247-61. PubMed ID: 25690090
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Physical stability of amorphous pharmaceutical solids: Nucleation, crystal growth, phase separation and effects of the polymers.
    Shi Q; Li F; Yeh S; Wang Y; Xin J
    Int J Pharm; 2020 Nov; 590():119925. PubMed ID: 33011255
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.
    Mohsin K; Alamri R; Ahmad A; Raish M; Alanazi FK; Hussain MD
    Int J Nanomedicine; 2016; 11():2829-38. PubMed ID: 27366063
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Delivery of poorly soluble compounds by amorphous solid dispersions.
    Lee TW; Boersen NA; Hui HW; Chow SF; Wan KY; Chow AH
    Curr Pharm Des; 2014; 20(3):303-24. PubMed ID: 23651395
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
    Banerjee S; Pillai J
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
    [No Abstract]   [Full Text] [Related]  

  • 73. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
    Qian F; Huang J; Hussain MA
    J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oral bioavailability enhancement through supersaturation: an update and meta-analysis.
    Fong SY; Bauer-Brandl A; Brandl M
    Expert Opin Drug Deliv; 2017 Mar; 14(3):403-426. PubMed ID: 27488049
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Melt extrusion with poorly soluble drugs.
    Shah S; Maddineni S; Lu J; Repka MA
    Int J Pharm; 2013 Aug; 453(1):233-52. PubMed ID: 23178213
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Drug release from liquisolid systems: speed it up, slow it down.
    Nokhodchi A; Hentzschel CM; Leopold CS
    Expert Opin Drug Deliv; 2011 Feb; 8(2):191-205. PubMed ID: 21222556
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs.
    Hu J; Johnston KP; Williams RO
    Drug Dev Ind Pharm; 2004 Mar; 30(3):233-45. PubMed ID: 15109023
    [TBL] [Abstract][Full Text] [Related]  

  • 78. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs.
    Wang XQ; Zhang Q
    Eur J Pharm Biopharm; 2012 Oct; 82(2):219-29. PubMed ID: 22885229
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
    Meng F; Gala U; Chauhan H
    Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Enhanced Drug Delivery by Dissolution of Amorphous Drug Encapsulated in a Water Unstable Metal-Organic Framework (MOF).
    Suresh K; Matzger AJ
    Angew Chem Int Ed Engl; 2019 Nov; 58(47):16790-16794. PubMed ID: 31550411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.